pharmaphorum

FEBRUARY 5, 2021

In the second part of this series taking stock of t he 2019 Voluntary Scheme for Branded Medicines Pricing and Access objectives, Leela Barham looks at the second VPAS objective that relates to affordability (spoiler alert: government gets millions in payments). About the author.

Branding 71

Branding Medicine Sales Marketing 71

pharmaphorum

NOVEMBER 17, 2022

Leela Barham argues that more transparency at a minimum is required next time around, should a VPAS style of agreement be agreed upon for 2024 onwards, and perhaps even a more radical re-think about how a deal is struck in the future. About the author. But could it be better than what has been done since 1957?

Sales 98

Sales Branding Medicine Nurses 98

pharmaphorum

NOVEMBER 16, 2021

In the second of a two-part series, Leela Barham argues that whilst international comparisons of uptake are useful, there could be more to gain from looking at more medicines and their uptake in England rather than looking at a small set of medicines and their uptake internationally. About the author.

Medicine 90

Medicine Branding Gene Therapy Life Science 90

pharmaphorum

AUGUST 17, 2022

The indicators did not bring universal good news , but Leela Barham argues we need to consider whether the indicators are measuring what matters most if we are to understand more about the health of the UK life sciences industry and, most importantly, what it means for patients. About the author.

Life Science 57

Life Science Medicine Marketing Regulation 57

pharmaphorum

NOVEMBER 11, 2021

In part one of a two-piece series, Leela Barham looks at whether we are getting better at measuring international uptake of medicines. About the author. Leela worked as an advisor to the Department of Health and Social Care on the 2019 Voluntary Scheme for Branded Medicines Pricing and Access (VPAS).

Medicine 52

Medicine Branding Life Science Marketing 52

pharmaphorum

OCTOBER 24, 2022

With the IMF not yet used, but based on the Cancer Drugs Fund (CDF), Leela Barham used a freedom of information request to find out how the CDF spend is treated, and speculates as to what that might mean for the IMF. About the author. 2019 VPAS shapes commercial realities for companies.

Sales 75

Sales Branding Medicine Marketing 75

pharmaphorum

DECEMBER 8, 2022

Leela Barham calls for more transparency on the LSC when it’s needed most. About the author. Leela Barham is a researcher and writer who has worked with all stakeholders across the health care system, both in the UK and internationally, on the economics of the pharmaceutical industry. Life Sciences Council.

Life Science 102

Life Science Medicine Branding Research 102

pharmaphorum

APRIL 22, 2022

In March 2022 , Leela Barham argued that, in light of new highs in the number of non-submissions to UK’s HTA agency, NICE, it was time to ask companies why they choose not to submit. About the author. ABPI survey. That said, the ABPI survey still doesn’t provide the views of individual companies!

Branding 57

Branding Medicine Marketing Production 57

pharmaphorum

JULY 13, 2021

Leela Barham provides an independent view of patient organisations responses to a NICE online survey and highlights the opportunity for other stakeholders to share their views on NICE through an online survey open until 16 July 2021. About author. Take ten minutes and let NICE know what you think.

Medicine 57

Medicine Branding Marketing Development 57

pharmaphorum

FEBRUARY 1, 2021

In the latest of a suite of features looking at the biggest markets in Europe, Leela Barham takes stock of what 2021 could bring for market access in Italy. About the author. Leela worked as an advisor to the Department of Health and Social Care on the 2019 Voluntary Scheme for Branded Medicines Pricing and Access (VPAS).

Marketing 52

Marketing Medicine Pharmacy Gene Therapy 52

pharmaphorum

JANUARY 20, 2023

Leela Barham argues that the latest operational guidance for the NHS in England continues to illustrate a disconnect between the messages in big-ticket policy documents from the central government and the messages from the NHS in England on medicines. On the money side, all stakeholders need to get their thinking caps on!

Medicine 103

Medicine Branding Life Science Production 103

pharmaphorum

OCTOBER 29, 2020

With exclusive data from Freedom of Information (FOI) requests sent to the National Institute for Health and are Excellence (NICE), Leela Barham takes a look at the trend in early engagement with the UK’s HTA body. About the author.

Marketing 99

Marketing Production Development Clinical Trials 99

pharmaphorum

FEBRUARY 9, 2021

In the final instalment of our series reviewing the t he 2019 Voluntary Scheme for Branded Medicines Pricing and Access (VPAS), Leela Barham takes stock of the whole scheme after digging more deeply into its three objectives. About the author. It makes for an agreement which is neither a legal document nor a policy one.

Life Science 69

Life Science Branding Medicine Sales 69

pharmaphorum

MARCH 9, 2022

Leela Barham looks at what has been happening to the number of non-submissions at NICE, updating on trends last looked at in 2020. About the author. Leela worked as an advisor to the Department of Health and Social Care on the 2019 Voluntary Scheme for Branded Medicines Pricing and Access (VPAS).

Branding 52

Branding Medicine Marketing Life Science 52

pharmaphorum

JUNE 14, 2021

Now that VPAS has hit the mid-point and stakeholders are already thinking ahead to the next deal, Leela Barham delves further. About the author. Leela worked as an advisor to the Department of Health and Social Care on the 2019 Voluntary Scheme for Branded Medicines Pricing and Access (VPAS).

Branding 109

Branding Drugs Medicine Marketing 109

pharmaphorum

SEPTEMBER 4, 2020

Leela Barham asks why companies may choose to not submit their drugs to NICE and keep them off routine commissioning – a trend that appears to be on the rise. About the author. Leela worked as an advisor to the Department of Health and Social Care on the 2019 Voluntary Scheme for Branded Medicines Pricing and Access (VPAS).

Medicine 62

Medicine Marketing Trials Branding 62

pharmaphorum

JANUARY 12, 2021

Looking back at key market access news from the last year, Leela Barham takes stock of what the next twelve months could bring for UK market access. About the author. Leela worked as an advisor to the Department of Health and Social Care on the 2019 Voluntary Scheme for Branded Medicines Pricing and Access (VPAS).

Marketing 67

Marketing Medicine Branding Production 67

pharmaphorum

FEBRUARY 4, 2021

With the current deal two years into the five-year agreement, Leela Barham takes stock on each objective, starting with the first objective that relates to patients (spoiler alert: not much). About the author. The full deal is set out in the 2019 Voluntary Scheme for Branded Medicines Pricing and Access (VPAS).

Medicine 88

Medicine Branding Production Marketing 88

pharmaphorum

FEBRUARY 16, 2022

Leela Barham and Neil Grubert look back at what was expected for market access in 2021 and look ahead at what 2022 could hold. About the authors. Leela worked as an advisor to the Department of Health and Social Care on the 2019 Voluntary Scheme for Branded Medicines Pricing and Access (VPAS).

Marketing 52

Marketing Life Science Medicine Gene Therapy 52